Morgan Stanley Maintains Overweight Rating on Hengrui Pharma (01276) with HK$82 Target Price
Stock News
Yesterday
Morgan Stanley has released a research report maintaining a target price of HK$82 and an "Overweight" rating for Hengrui Pharma (01276).
The firm noted that the once-weekly oral treatment space remains at a very early stage, with a limited number of global competitors. A US$300 million upfront payment is considered "quite substantial" for an asset still in IND/Phase 1 stage.
The transaction once again reflects that global pharmaceutical companies continue to place significant importance on the obesity market, and Hengrui Pharma's GLP-1 platform possesses global competitiveness.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.